Organogenesis (ORGO) to Release Quarterly Earnings on Wednesday

Organogenesis (NASDAQ:ORGO) is scheduled to announce its earnings results after the market closes on Wednesday, August 9th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Wednesday, May 10th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $107.64 million during the quarter. Organogenesis had a net margin of 2.92% and a return on equity of 8.03%. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Stock Down 8.3 %

Shares of NASDAQ ORGO opened at $3.87 on Monday. Organogenesis has a 52-week low of $1.79 and a 52-week high of $6.52. The business has a 50-day moving average price of $3.84 and a 200 day moving average price of $2.93. The company has a quick ratio of 2.51, a current ratio of 2.85 and a debt-to-equity ratio of 0.25. The stock has a market cap of $507.98 million, a PE ratio of 35.19 and a beta of 1.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ORGO. State Street Corp boosted its position in shares of Organogenesis by 39.6% during the second quarter. State Street Corp now owns 6,170,589 shares of the company’s stock worth $30,112,000 after buying an additional 1,750,534 shares during the period. BlackRock Inc. raised its stake in Organogenesis by 17.1% during the 1st quarter. BlackRock Inc. now owns 9,652,188 shares of the company’s stock valued at $73,551,000 after purchasing an additional 1,412,356 shares during the period. Federated Hermes Inc. raised its stake in Organogenesis by 1,086.6% during the 1st quarter. Federated Hermes Inc. now owns 1,030,743 shares of the company’s stock valued at $7,854,000 after purchasing an additional 943,875 shares during the period. AQR Capital Management LLC increased its stake in shares of Organogenesis by 70.0% in the fourth quarter. AQR Capital Management LLC now owns 2,190,565 shares of the company’s stock worth $5,893,000 after acquiring an additional 902,291 shares during the last quarter. Finally, Soleus Capital Management L.P. increased its stake in shares of Organogenesis by 13.5% in the fourth quarter. Soleus Capital Management L.P. now owns 7,363,063 shares of the company’s stock worth $19,807,000 after acquiring an additional 874,000 shares during the last quarter. Institutional investors and hedge funds own 40.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. BTIG Research raised Organogenesis from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, May 23rd. Morgan Stanley began coverage on Organogenesis in a report on Thursday, June 15th. They set an “equal weight” rating on the stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.